Portal de Periódicos da CAPES

Inclusion body myositis and myopathies

1995; Wiley; Volume: 38; Issue: 5 Linguagem: Inglês

10.1002/ana.410380504

1531-8249

Robert C. Griggs, Valerie Askanas, Salvatore DiMauro, Andrew Engel, George Karpati, Jerry R. Mendell, Lewis P. Rowland,

Dermatological and Skeletal Disorders

Annals of NeurologyVolume 38, Issue 5 p. 705-713 Neurological Progress Inclusion body myositis and myopathies Dr Robert C. Griggs MD, Corresponding Author Dr Robert C. Griggs MD University of Rochester, Rochester, NYUniversity of Rochester School of Medicine and Dentistry, Department of Neurology, 601 Elmwood Avenue, Box 673, Rochester, NY 14642Search for more papers by this authorValerie Askanas MD, PhD, Valerie Askanas MD, PhD Department of Neurology, University of Southern California School of Medicine, Los Angeles, CASearch for more papers by this authorSalvatore DiMauro MD, Salvatore DiMauro MD College of Physicians and Surgeons, New YorkSearch for more papers by this authorAndrew Engel MD, Andrew Engel MD Mayo Clinic, Rochester, MNSearch for more papers by this authorGeorge Karpati MD, George Karpati MD Montreal Neurological Institute, Montreal, Quebec, CanadaSearch for more papers by this authorJerry R. Mendell MD, Jerry R. Mendell MD Ohio State University, Columbus, OHSearch for more papers by this authorLewis P. Rowland MD, Lewis P. Rowland MD Neurological Institute, Columbia-Presbyterian Medical Center, New York, NYSearch for more papers by this author Dr Robert C. Griggs MD, Corresponding Author Dr Robert C. Griggs MD University of Rochester, Rochester, NYUniversity of Rochester School of Medicine and Dentistry, Department of Neurology, 601 Elmwood Avenue, Box 673, Rochester, NY 14642Search for more papers by this authorValerie Askanas MD, PhD, Valerie Askanas MD, PhD Department of Neurology, University of Southern California School of Medicine, Los Angeles, CASearch for more papers by this authorSalvatore DiMauro MD, Salvatore DiMauro MD College of Physicians and Surgeons, New YorkSearch for more papers by this authorAndrew Engel MD, Andrew Engel MD Mayo Clinic, Rochester, MNSearch for more papers by this authorGeorge Karpati MD, George Karpati MD Montreal Neurological Institute, Montreal, Quebec, CanadaSearch for more papers by this authorJerry R. Mendell MD, Jerry R. Mendell MD Ohio State University, Columbus, OHSearch for more papers by this authorLewis P. Rowland MD, Lewis P. Rowland MD Neurological Institute, Columbia-Presbyterian Medical Center, New York, NYSearch for more papers by this author First published: November 1995 https://doi.org/10.1002/ana.410380504Citations: 582AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Yunis EJ, Samaha FJ. Inclusion body myositis. Lab Invest 1971; 25: 240–248 2 Chou SM. Myxovirus-like structures in a case of human chronic polymyositis. Science 1967; 158: 1453–1455 3 Carpenter S, Karpati G, Heller I, Eisen A. Inclusion body myositis: a distinct variety of idiopathic inflammatory myopathy. Neurology 1978; 28: 8–17 4 Dalakas MC. Polymyositis, dermatomyositis, and inclusion body myositis. N Engl J Med 1991; 325: 1487–1498 5 Askanas V, Engel WK, Mirabella M. Idiopathic inflammatory myopathies: inclusion body myositis, polymyositis, and dermatomyositis. Curr Opin Neurol 1994; 7: 448–456 6 Sayers ME, Chou SM, Calabrese LH. Inclusion body myositis: analysis of 32 cases. J Rheumatol 1992; 19: 1385–1389 7 Sekul EA, Dalakas MC. Inclusion body myositis: new concepts. Semin Neurol 1993; 13: 256–263 (Review) 8 Mendell JR, Sahenk Z, Gales T, Paul L. Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments. Arch Neurol 1991; 48: 1229–1234 9 Askanas V, Engel WK, Alverez RB. Enhanced detection of Congo-red-positive amyloid deposits in muscle fibers of inclusion-body myositis and brain of Alzheimer disease using fluorescence technique. Neurology 1993; 43: 1265–1267 10 Sarkozi B, Askanas V, Engel WK. Abnormal accumulation of prion protein mRNA in muscle fibers of patients with sporadic inclusion-body myositis and hereditary inclusion-body myopathy. Am J Pathol 1994; 145: 1280–1284 11 Askanas V, Engel WK, Bilak M, et al. Twisted tubulofilaments of inclusion-body myositis muscle resemble paired helical filaments of Alzheimer brain containing hyperphosphorylated tau. Am J Pathol 1994; 144: 177–187 12 Bush AI, Pettingell WH, Multhaup G, et al. Rapid induction of Alzheimer A beta amyloid formation by zinc. Science 1994; 265: 1464–1467 13 Westaway D, DeArmond SJ, Cayetano-Canias J, et al. Degeneration of skeletal muscle, peripheral nerves, and the central nervous system in transgenic mice overexpressing wild-type prion proteins. Cells 1994; 76: 117–129 14 Kowall NW, McKee AC. The histopathology of neuronal degeneration and plasticity in Alzheimer disease. Neurology 1993; 59: 5–33 15 Engel AG, Hohlfeld R, Banker BQ. Polymyositis and dermatomyositis. In: AG Engel, C Franzini-Armstrong, eds. Myology. 2nd ed. New York: McGraw-Hill, 1994: 1335–1383 16 Engel AG, Arahata K, Emslie-Smith A. Immune effector mechanisms in inflammatory myopathies. In: BH Waksman, ed. Immunologic mechanisms in neurologic and psychiatric disease. New York: Raven, 1990: 141–157 17 Lotz B, Engel AG, Nishino H, et al. Inclusion body myositis. Observations in 40 patients. Brain 1989; 112: 727–747 18 De Bleecker JL, Engel AG. Expression of cell adhesion molecules in inflammatory myopathies and Duchenne dystrophy. J Neuropathol Exp Neurol 1994; 53: 369–376 19 Pruitt JN, Showalter CJ, Engel AG. Frequencies of Congo-red-positive fibers, T-cell-invaded fibers, and necrotic fibers in sporadic inclusion-body myositis. Neurology 1995; 45 (suppl 4): A 208 (Abstract) 20 O'Hanlon TP, Dalakas MC, Plotz PH, Miller FW. The alphabeta T-cell receptor repertoire in inclusion body myositis: diverse patterns of gene expression by muscle-infiltrating lymphocytes. J Autoimmun 1994; 7: 321–333 21 O'Hanlon TP, Dalakas MC, Plotz PH, Miller FW. Predominant TCR alphabeta variable and joining gene expression by muscle-infiltrating lymphocytes in the idiopathic inflammatory myopathies. J Immunol 1994; 152: 2569–2576 22 Mantegazza R, Andreetta F, Bernasconi P, et al. Analysis of T cell receptor repertoire of muscle-infiltrating T lymphocytes in polymyositis. Restricted V alpha/beta rearrangements may indicate antigen-driven selection. J Clin Invest 1993; 91: 2880–2886 23 Mantegazza RF, Bernasconi P, Torchiana E, et al. Molecular analysis of T cell receptor repertoire of T cell infiltrates in sporadic and familial inclusion body myositis. Muscle Nerve 1994; 17(suppl 1): S117 (Abstract) 24 Lindberg C, Oldfors A, Tarkowski A. Restricted use of T cell receptor V genes in endomysial infiltrates of patients with inflammatory myopathies. Eur J Immunol 1994; 24: 2659–2663 25 Bender A, Ernst N, Iglesias A, et al. T cell repertoire in polymyositis: clonal expansion of autoaggressive CD8+ T cells. J Exp Med 1995; 181: 1863–1868 26 Karpati G, Carpenter S. Pathology of the inflammatory myopathies. Baillieres Clin Neurol 1993; 2: 527–556 (Review) 27 Nalbantoglu J, Karpati G, Carpenter S. Conspicuous accumulation of a single-stranded DNA binding protein in skeletal muscle fibers in inclusion body myositis. Am J Pathol 1994; 144: 874–882 28 Seroussi E, Lavi S. Replication protein A is the major single-stranded DNA binding protein detected in mammalian cell extracts by gel retardation assays and UV cross-linking of long and short single-stranded DNA molecules. J Biol Chem 1993; 268: 7147–7154 29 Tomé FMS, Fareau M. Nuclear inclusions in oculopharyngeal dystrophy. Acta Neuropathol (Berl) 1980; 49: 85–87 30 Berezney R. The nuclear matrix: a heuristic model for investigating genomic organization and function in the cell nucleus. J Cell Biochem 1991; 47: 109–123 (Review) 31 Getzenberg RH, Pienta KJ, Ward WS, Coffey DS. Nuclear structure and the three-dimensional organization of DNA. J Cell Biochem 1991; 47: 289–299 (Review) 32 Leonhardt H, Page AW, Weier HU, Bestor TH. A targeting sequence directs DNA methyltransferase to sites of DNA replication in mammalian nuclei. Cell 1992; 71: 865–873 33 Sekul EA, Dalakas M. Inclusion body myositis: new concepts. Semin Neurol 1993; 13: 256–263 34 Oldfors A, Larsson NG, Lindberg C, Holme E. Mitochondrial DNA deletions in inclusion body myositis. Brain 1993; 116: 325–336 35 Simonetti S, Chen X, DiMauro S, Schon EA. Accumulation of deletions in human mitochondrial DNA during normal aging: analysis by quantitative PCR. Biochim Biophys Acta 1992; 1180: 113–122 36 Cortopassi G, Arnheim N. Accumulation of mitochondrial DNA mutation in normal aging brain and muscle. In: S DiMauro, DC Wallace, eds. Mitochondrial DNA in human pathology. New York: Raven, 1993: 125–136 37 Johnston W, Karpati G, Carpenter S, et al. Late-onset mitochondrial myopathy. Ann Neurol 1995; 37: 16–23 38 Mendell JR. Mitochondrial myopathy in the elderly: exaggerated aging in the pathogenesis of the disease. Ann Neurol 1995; 37: 3–4 39 S DiMauro, DC Wallace, eds. Mitochondrial DNA in human pathology. New York: Raven, 1993 40 Zeviani M, Servidei S, Gellera C, et al. An autosomal dominant disorder with multiple deletions of mitochondrial DNA starting at the D-loop region. Nature 1989; 339: 309–311 41 Suomalainen A, Majander A, Haltia M, et al. Multiple deletions of mitochondrial DNA in several tissues of a patient with severe retarded depression and familial progressive external ophthalmoplegia. J Clin Invest 1992; 90: 61–66 42 Zeviani M, Tiranti V. Inherited mendelian defects. In: S DiMauro. DC Wallace. eds. Mitochondrial DNA in human pathology. New York: Raven, 1993: 85–95 43 Suomalainen A, Kaukonen J, Amati P, et al. An autosomal locus predisposing to deletions of mitochondrial DNA. Nature Genet 1995; 9: 146–151 44 Neville HE, Baumbach LL, Ringel SP, et al. Familial inclusion body myositis: evidence for autosomal dominant inheritance (see comments). Neurology 1992; 42: 897–902 45 Speer MC, Yamaoka LH, Gilchrist JH, et al. Confirmation of genetic heterogeneity in limb-girdle muscular dystrophy: linkage of an autosomal dominant form to chromosome 5q. Am J Hum Genet 1992; 50: 1211–1217 46 Argov Z, Yarom R. “Rimmed vacuole myopathy” sparing the quadriceps. A unique disorder in Iranian Jews. J Neurol Sci 1984; 64: 33–43 47 Brais B, Xie YG, Sanson M, et al. The oculopharyngeal muscular dystrophy locus maps to the region of the cardiac α and β myosin heavy chain genes on chromosome 14q 11.2-q 13. Hum Mol Genet 1995; 4: 429–434 48 Griggs RC, Markesbery WR. Distal myopathies. In: AG Engel, C Franzini-Armstrong, eds. Myology vol 2. 2nd ed. New York: McGraw-Hill, 1994: 1246–1257 49 Somer H. Distal myopathies. Workshop report from 25th ENMC International Workshop 18–20 November 1994, Naarden, the Netherlands. Neuromusc Dis 1995; 5: 249–252 50 Udd B, Partanen J, Halonen P, et al. Tibial muscular dystrophy. Late adult-onset distal myopathy in 66 Finnish patients. Arch Neurol 1993; 50: 604–608 51 Danon MJ, Reyes MG, Perurena OH, et al. Inclusion body myositis. A corticosteroid-resistant idiopathic inflammatory myopathy. Arch Neurol 1982; 39: 760–764 52 Leff RL, Miller FW, Hicks J, et al. The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy. Medicine 1993; 72: 225–235 53 Barohn RJ, Amato AA, Sahenk Z, et al. Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurology 1995; 45: 1302–1304 54 Soueidan SA, Dalakas MC. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology 1993; 43: 876–879 55 Dalakas MC, Dambrosia JM, Sekul EA, et al. The efficacy of high-dose intravenous immunoglobulin in patients with inclusion-body myositis. Neurology 1995; 45 (S): 208 (Abstract) 56 Amato AA, et al. Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology 1994; 44: 1516–1518 57 Thornton C, Welle S. No suppression of endogenous IgG production following treatment with intravenous immunoglobulin (IVIG). Neurology 1995; 45 (suppl 4): A235–A236 58 Basta M, Dalakas MC. High dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994; 94: 1729–1735 Citing Literature Volume38, Issue5November 1995Pages 705-713 ReferencesRelatedInformation